Analyst predicts Dendreon bankruptcy; Sinovac begins H7N9 vax production;

> An analyst has set a $0 stock price target for cancer vaccine maker Dendreon ($DNDN). The target is based on a belief that the firm's debt and weak sales are pushing it toward bankruptcy. Feature

> Beijing-based Sinovac Biotech has completed preliminary work on the manufacturing of an H7N9 vaccine. News

> Northwestern Medical has joined a Phase II trial investigating a personalized brain tumor vaccine given in combination with Avastin. Release

> Tanzania has seen no serious side effects after administering 11,000 HPV vaccines. Article

> The U.K. advertising watchdog has criticized a clinic's measles vaccine promotion. Item

> India has reportedly resolved its yellow fever vaccine shortage. Piece

> The H1N1 influenza virus has killed 35 people in India in 2013. News

> Inovio Pharmaceuticals ($INO) has reported positive preclinical data for its malaria vaccine. Article

> Arbovax is seeking VC funding to support a clinical trial of a dengue fever vaccine. Piece